Respiratory Chain Complexes and OXPHOS-Deficient Models
The Three Deficiencies
| Deficiency | Meaning | Readout |
|---|---|---|
| Capacity | Reduced maximal electron transport | Maximal OCR after uncoupler titration |
| Coupling | Electron transport continues but ATP synthesis is weak | Oligomycin-sensitive fraction; respiratory control ratio |
| Content | Fewer mitochondria | mtDNA copy number; complex subunit abundance |
Important distinction. A cell can have normal capacity and poor coupling, or reduced content with normal per-mitochondrion function. Because OCR is the product of all three, a fall in OCR alone does not identify which changed. Measuring maximal respiration, the oligomycin-sensitive fraction, and a content marker separates them.
Part 1 — The Complexes
| Complex | Subunits | mtDNA-encoded | Notable features |
|---|---|---|---|
| I (NADH dehydrogenase) | ~45 | 7 | Largest; L-shaped; major site of superoxide production at reverse electron transfer |
| II (succinate dehydrogenase) | 4 | 0 | Also a TCA enzyme; entirely nuclear-encoded |
| III (cytochrome bc₁) | 11 | 1 | Q cycle; superoxide at Qo site |
| IV (cytochrome c oxidase) | 13 | 3 | Terminal oxidase; oxygen reduction |
| V (ATP synthase) | ~17 | 2 | Rotor; dimer rows shape cristae |
Important distinction. Complex II is the only complex with no mtDNA-encoded subunits, which means that ρ0 cells — which lack a mitochondrial genome — retain complex II activity. This is why succinate-linked respiration is preserved in ρ0 cells and is used as a control for mitochondrial content rather than for respiratory competence.
Part 2 — The Models
| Model | How it is made | What it models | Caveat |
|---|---|---|---|
| ρ0 cells | Long-term low-dose ethidium bromide or ddC | Absence of mtDNA-encoded subunits | Requires uridine and pyruvate; extensive adaptation |
| Complex I knockout | CRISPR of a nuclear subunit (NDUFA9, NDUFS1) | Loss of complex I | Lethal in some lines; compensatory changes |
| Complex I point mutants | Patient-derived or edited variants | Partial deficiency | Heteroplasmy in mtDNA variants |
| Cybrids | Transfer of patient mtDNA into ρ0 background | mtDNA variant effects | Nuclear background matched; clonal selection |
| Chemical inhibition | Rotenone, piericidin, antimycin | Acute loss of a complex | Off-target and ROS effects |
Caveat on ρ0 cells. They are not simply "cells without OXPHOS". They require uridine (because the pyrimidine synthesis step involving dihydroorotate dehydrogenase is mitochondrial) and often pyruvate (as an NAD⁺ regeneration route), and they adapt over weeks: glycolytic capacity increases, mitochondrial mass may change, and some signalling pathways are altered. A phenotype in ρ0 cells is therefore a phenotype of long-term adaptation to mtDNA loss, not of acute OXPHOS inhibition.
Part 3 — What Each Readout Establishes
| Readout | Establishes | Does not establish |
|---|---|---|
| Basal OCR | Electron transport under assay substrates | Capacity; coupling |
| Maximal OCR after titrated uncoupler | Capacity | Whether capacity is used |
| Oligomycin-sensitive OCR | ATP-linked fraction | Total ATP production (other routes contribute) |
| Respiratory control ratio | Coupling quality | Capacity |
| mtDNA copy number | Content | Function |
| Complex subunit immunoblot | Content of that subunit | Assembly or activity |
| Blue-native gel | Complex and supercomplex assembly | Activity |
| Isolated complex activity | Enzyme activity | Cellular flux |
Readout note. Blue-native PAGE is the only routine method that reports assembly, and it is the readout that distinguishes a subunit loss from a loss of holocomplex. Without it, a normal subunit immunoblot in a functionally deficient line is unexplained — and that pattern is common, because assembly defects degrade individual subunits at different rates.
Part 4 — Supercomplexes and Cristae
Respiratory complexes assemble into supercomplexes (I+III₂+IV), and ATP synthase forms dimer rows that shape cristae curvature.
| Feature | Consequence | Measurement |
|---|---|---|
| Supercomplex assembly | May improve electron transfer efficiency and reduce superoxide | Blue-native PAGE |
| ATP synthase dimer rows | Cristae curvature; affects proton gradient localisation | Electron microscopy; blue-native |
| Cristae density | Surface area for the ETC | Electron microscopy, tomography |
| OPA1-dependent cristae remodelling | Regulates cytochrome c release and respiratory efficiency | OPA1 cleavage forms; imaging |
Caveat on inference. Supercomplex abundance correlates with efficiency in some systems and not others, and the causal direction is debated. A change in supercomplexes is a structural observation; a claim that it changed respiratory efficiency requires a functional measurement alongside.
Part 5 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Uridine and pyruvate for ρ0 | Otherwise the cells do not grow |
| Documented passage after ρ0 generation | Adaptation accumulates |
| Capacity and coupling measured separately | OCR alone conflates them |
| Content marker alongside function | Separates content from specific activity |
| Complex II-linked respiration as control | Preserved in ρ0; validates the assay |
| Substrate-specific respiration | Basal rate depends on substrate |
Recurring failures:
- • ρ0 cells described as "OXPHOS-deficient" without acknowledging the auxotrophy and adaptation.
- • Basal OCR reported as capacity.
- • mtDNA copy number reported as function.
- • Complex I inhibition used as a model of complex I loss, when rotenone also generates superoxide.
- • A single complex subunit blot used to conclude assembly status.
- • ρ0 phenotype attributed to OXPHOS, when uridine or pyruvate availability changed.
- • No complex II control, so a global assay failure looks like a specific defect.
Part 6 — Where This Article Connects
This is the respiratory-chain article of the mitochondrial cluster: it supplies the models that the OXPHOS-dependency discussion in the pillar refers to, and the readouts that the Seahorse protocol article implements. The membrane potential article covers coupling in more detail; the inhibitor article covers the pharmacological alternatives.
If you need OXPHOS-deficient models with capacity, coupling and content measured separately, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Complex abundance, assembly and coupling vary with cell type, passage and culture conditions, and ρ0 adaptation differs between lines. The models here are described at the level of principle.
Reduced oxygen consumption does not establish an ETC defect, and an ETC defect does not establish that ATP supply limits a phenotype.
Scientific interpretation and experimental design
- • Three deficiencies, three readouts. Capacity, coupling, content.
- • ρ0 is an adaptation, not an acute knockout. Account for uridine and pyruvate.
- • Complex II survives mtDNA loss. Use it as the control.
- • Assembly needs blue-native PAGE.
- • Inhibitors make superoxide. That is a confound, not a detail.
- • Copy number is content.
Selected references for further reading
- • King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246:500–503.
- • Letts JA, Sazanov LA. Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain. Nature Structural & Molecular Biology. 2017;24:800–808.
- • Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nature Reviews Molecular Cell Biology. 2022;23:141–161.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »